Author(s)
Fatima Amanat
Published 24 Projects
Infectious Diseases Epidemiology Allergy And Immunology Immunology Covid19
Shirin Strohmeier
Published 9 Projects
Immunology Microbiology Infectious Diseases Allergy And Immunology Influenza
Andrew B. Ward
Published 9 Projects
Immunology Microbiology Synthetic Biology Influenza Hemagglutinin Stalk
Lynda Coughlan
Published 5 Projects
Immunology Microbiology Influenza Hemagglutinin Stalk Universal Vaccine
Content
After first emerging in December 2019 in China, severe acute respiratory syndrome 2 (SARS-CoV-2) has since caused a pandemic leading to millions of infections and deaths worldwide. Vaccines have been developed and authorized but supply of these vaccines is currently limited. With new variants of the virus now emerging and spreading globally, it is essential to develop therapeutics that are broadly protective and bind conserved epitopes in the receptor binding domain (RBD) or the whole spike of SARS-CoV-2. In this study, we have generated mouse monoclonal antibodies (mAbs) against different epitopes on the RBD and assessed binding and neutralization against authentic SARS-CoV-2. We have demonstrated that antibodies with neutralizing activity, but not non-neutralizing antibodies, lower viral titers in the lungs when administered in a prophylactic setting in vivo in a mouse challenge model. In addition, most of the mAbs cross-neutralize the B.1.351 as well as the B.1.1.7 variants in vitro.
More Projects
Loren Frank
13 views • 2 years ago
Global Immunotalks
390 views • 2 years ago
Laurel Yohe
2 views • 2 years ago
Global Immunotalks
130 views • 2 years ago
Jignesh H. Parmar
0 views • 1 year ago
Winston A. Haynes
0 views • 1 year ago
Noam Mazor
0 views • 1 year ago
Global Immunotalks
182 views • 2 years ago
Cem Yuksel
345 views • 2 years ago
Oscar Gonzalez-Recio
3 views • 2 years ago
Please pick a style:
Florian Krammer. (2021, Oct 30).Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner[Video]. Scitok. https://scitok.com/project/p/a192b885
Amanat Fatima. "Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner" Scitok, uploaded by Krammer Florian, 30 Oct, 2021, https://scitok.com/project/pa192b885
Florian Krammer. "Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner" Scitok. (Oct 30, 2021). https://scitok.com/project/p/a192b885
Florian Krammer (Oct 30, 2021). Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner Scitok. https://scitok.com/project/p/a192b885
Florian Krammer. Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner[video]. 2021 Oct 30. https://scitok.com/project/p/a192b885
@online{al2006link, title={ Murine monoclonal antibodies against RBD of SARS-CoV-2 neutralize authentic wild type SARS-CoV-2 as well as B.1.1.7 and B.1.351 viruses and protect in vivo in a mouse model in a neutralization dependent manner }, author={ Krammer, Florian }, organization={Scitok}, month={ Oct }, day={ 30 }, year={ 2021 }, url = {https://scitok.com/project/p/a192b885}, }